Sascha is a Co-Founder and Partner of FORTY51 Ventures, a novel venture capital fund focused on company building and early-stage investments in European biotech. Sascha has more than 25 years of experience in Pharma and Biotech.
Before co-founding FORTY51 Sascha was the Head of Global Transactions at Roivant and Head of Roivant Europe, where he was a member of the company’s Investment Committee and built Roivant’s European operations.
Before that he spent a long career across different functions at the Roche/Genentech Group, including managerial roles in investments, partnering and business development. In his last role as Roche’s Deputy Global Head of M&A he oversaw and led international transactions including many of Roche’s landmark deals from start to finish.
He started his career as a banker at UBS. Over the course of his career he has lead over 50 closed transactions (investments, partnering, M&A).
Besides his board role at Mosanna, he currently serves on several boards including Tarsier Pharma and Altavant GmbH.
Sascha holds an MBA from the University of Basel, is a GMP alumnus of Harvard Business School and a certified Financial Analyst (EFFAS).